Physician profile
Bailey Alai
NPI 1891417713
$12,621.28
in general payments reported to CMS, 2019-2025
25 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $443 · 2023: $6,656 · 2024: $4,011 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,643.97 |
| Education | $533.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,827.40 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,593.72 | 2023-2025 | Skyrizi, Rinvoq, Humira |
| Incyte Corporation | $1,201.47 | 2022-2025 | Opzelura |
| Genzyme Corporation | $1,007.76 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $934.20 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $844.77 | 2023-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $739.24 | 2023-2024 | Sotyktu |
| Lilly USA, LLC | $581.55 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $437.01 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $421.60 | 2023-2025 | Zoryve |
| Amgen INC. | $410.38 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $355.80 | 2023-2024 | Vtama |
| Ucb, INC. | $342.48 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $294.32 | 2023-2024 | |
| Sandoz INC. | $137.21 | 2023-2024 | Hyrimoz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.11 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.90 | 2023 | Spevigo, Cyltezo |
| Organon LLC | $103.73 | 2023-2024 | Hadlima |
| Mylan Institutional INC. | $44.80 | 2023 | Hulio |
| Blueprint Medicines Corporation | $25.35 | 2023 | Ayvakit |
| Verrica Pharmaceuticals INC. | $24.61 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.57 | 2024 | Siliq, Duobrii |
| Biofrontera INC. | $18.50 | 2025 | Ameluz |
| Strata Skin Sciences, INC. | $16.05 | 2025 | Xtrac |
| Organogenesis INC. | $13.75 | 2025 | Cygnus Dual |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Alai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.